Literature DB >> 32304704

T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma.

Maya Farah1, Alexandre Reuben2, Ivelina Spassova3, Richard K Yang1, Linda Kubat3, Priyadharsini Nagarajan1, Jing Ning4, Wen Li4, Phyu P Aung1, Jonathan L Curry5, Carlos A Torres-Cabala6, Courtney W Hudgens7, Selma Ugurel8, Dirk Schadendorf8, Curtis Gumbs9, Latasha D Little9, Andrew Futreal9, Ignacio I Wistuba7, Victor G Prieto6, Linghua Wang9, Michael K Wong10, Jennifer A Wargo11, Jürgen C Becker12, Michael T Tetzlaff13.   

Abstract

The integrity of the immune system represents a pivotal risk factor and prognostic biomarker for Merkel cell carcinoma. A higher density of tumor-associated T cells correlates with improved Merkel cell carcinoma-specific survival, but the prognostic importance of the T-cell infiltrate reactivity is unknown. We evaluated the T-cell receptor repertoire associated with 72 primary Merkel cell carcinomas and correlated metrics of the T-cell receptor repertoire with clinicopathologic characteristics and patient outcomes. We showed that a high Simpson's Dominance index (SDom) was significantly associated with fewer metastases (P = 0.01), lower stage at presentation (P = 0.02), lower final stage at last follow-up (P = 0.05), and longer time to first lymph node metastasis (P = 0.04). These correlations were mostly preserved in the Merkel cell polyomavirus-negative subgroup. Combining SDom with CD3+ or CD8+ T-cell density revealed three distinct prognostic groups with respect to disease-specific survival. Patients with both high SDom and high CD3+ or CD8+ T-cell density had markedly improved disease-specific survival compared with patients with low SDom and low CD3+ or CD8+ T-cell density (P = 0.002 and P = 0.03, respectively). Patients with either high SDom or high CD3+ or CD8+ had intermediate disease-specific survival. Our findings demonstrate that the quality of the tumor-associated T-cell infiltrate informs patient prognosis in primary Merkel cell carcinoma beyond the T-cell density.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32304704     DOI: 10.1016/j.jid.2020.02.031

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.

Authors:  Ivelina Spassova; Selma Ugurel; Linda Kubat; Lisa Zimmer; Patrick Terheyden; Annalena Mohr; Hannah Björn Andtback; Lisa Villabona; Ulrike Leiter; Thomas Eigentler; Carmen Loquai; Jessica C Hassel; Thilo Gambichler; Sebastian Haferkamp; Peter Mohr; Claudia Pfoehler; Lucie Heinzerling; Ralf Gutzmer; Jochen S Utikal; Kai Horny; Hans-Ulrich Schildhaus; Daniel Habermann; Daniel Hoffmann; Dirk Schadendorf; Jürgen Christian Becker
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

2.  Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas Focusing on Tumor-Infiltrating Lymphocytes, MCPYV Infection and ALK Expression.

Authors:  Rebecca Senetta; Mauro Papotti; Federica Santoro; Francesca Maletta; Renato Parente; Jessica Fissore; Cristian Tampieri; Leonardo Santoro; Nadia Birocco; Franco Picciotto; Pietro Quaglino; Marco Volante; Sofia Asioli
Journal:  Endocr Pathol       Date:  2022-05-12       Impact factor: 4.056

Review 3.  Merkel Cell Carcinoma: New Trends.

Authors:  Ellen M Zwijnenburg; Satish F K Lubeek; Johanna E M Werner; Avital L Amir; Willem L J Weijs; Robert P Takes; Sjoert A H Pegge; Carla M L van Herpen; Gosse J Adema; Johannes H A M Kaanders
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

Review 4.  Merkel Cell Carcinoma.

Authors:  Elena Dellambra; Maria Luigia Carbone; Francesca Ricci; Francesco Ricci; Francesca Romana Di Pietro; Gaia Moretta; Sofia Verkoskaia; Elisa Feudi; Cristina M Failla; Damiano Abeni; Luca Fania
Journal:  Biomedicines       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.